Monashee Investment Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Monashee Investment Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100,000	Closed	-$1.22M	–	442
2020 Q4	$1.22M	Buy	+100,000	New	+$1.39M	0.16%	150
2020 Q3	–	Sell	-200,625	Closed	-$2.04M	–	278
2020 Q2	$2.04M	Buy	+200,625	New	+$1.85M	0.3%	99
2019 Q1	–	Sell	-62,500	Closed	-$718K	–	146
2018 Q4	$718K	Buy	+62,500	New	+$1.26M	0.49%	47
2017 Q4	–	Hold	0	–	–	–	112

Other funds holding MRNS

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Monashee Investment Management's MRNS Position: Q1 2021 in Review

Monashee Investment Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2021, closing a stake of 100,000 shares — an estimated $1.22M sold.

Monashee Investment Management first reported a position in MRNS in Q4 2018 and held it in 3 quarters. The position peaked at $2.04M in Q2 2020. 87 funds tracked by Wall St. Rank hold MRNS as of Q1 2021.

Monashee Investment Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2021 after selling out during the quarter.
Monashee Investment Management sold 100,000 Marinus Pharmaceuticals, Inc shares in Q1 2021, an estimated $1.22M.
Monashee Investment Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 3 quarters.
Monashee Investment Management's Marinus Pharmaceuticals, Inc position peaked at $2.04M in Q2 2020.
87 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2021.

Based on Monashee Investment Management's 13F filing for Q1 2021, filed 14 May 2021.